English Deutsch 中文
XinTech
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
XinTech
Menu Deutsch 中文

TJAB Forms Drug Development JV with Antisense of Australia

Jul. 17, 2012

July 18, 2012. Tianjin International Joint Academy of Biotechnology and Medicine (TJAB) has formed a JV with Antisense Technologies of Australia (ANP) to develop a drug discovered by ANP. The drug, ATL1102, is aimed at multiple sclerosis, stem cell mobilization and asthma.
TJAB will be responsible for commercialization of ATL1102 in China and Hong Kong, while ANP will be responsible for its commercialization in the rest of the world.